Media coverage about Tesaro (NASDAQ:TSRO) has been trending somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tesaro earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 44.7736898697192 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern’s rankings:
Shares of TSRO opened at $57.19 on Thursday. The company has a market capitalization of $3,025.57, a price-to-earnings ratio of -6.24 and a beta of 1.34. Tesaro has a twelve month low of $52.20 and a twelve month high of $168.92. The company has a debt-to-equity ratio of 1.75, a current ratio of 4.74 and a quick ratio of 4.39.
Tesaro (NASDAQ:TSRO) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.39) by ($0.96). The firm had revenue of $48.02 million during the quarter, compared to analyst estimates of $51.78 million. Tesaro had a negative net margin of 222.15% and a negative return on equity of 126.44%. equities analysts predict that Tesaro will post -9.46 earnings per share for the current fiscal year.
TSRO has been the topic of a number of research analyst reports. Credit Suisse Group restated an “outperform” rating and issued a $150.00 target price (down from $190.00) on shares of Tesaro in a research note on Thursday, January 18th. Barclays dropped their target price on shares of Tesaro from $135.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 28th. Cowen dropped their target price on shares of Tesaro from $125.00 to $80.00 and set a “market perform” rating on the stock in a research note on Tuesday, January 2nd. BidaskClub upgraded shares of Tesaro from a “strong sell” rating to a “sell” rating in a research note on Tuesday, January 23rd. Finally, Morgan Stanley dropped their price objective on shares of Tesaro from $165.00 to $156.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and fourteen have assigned a buy rating to the stock. Tesaro presently has a consensus rating of “Buy” and an average price target of $129.26.
In other news, CEO Leon O. Moulder, Jr. bought 5,000 shares of the stock in a transaction on Friday, March 2nd. The stock was bought at an average cost of $56.93 per share, for a total transaction of $284,650.00. Following the completion of the purchase, the chief executive officer now directly owns 1,018,828 shares in the company, valued at $58,001,878.04. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Timothy R. Pearson sold 2,575 shares of the firm’s stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $54.86, for a total transaction of $141,264.50. Following the completion of the sale, the chief financial officer now owns 7,303 shares of the company’s stock, valued at $400,642.58. The disclosure for this sale can be found here. Over the last 90 days, insiders acquired 334,913 shares of company stock valued at $19,083,294 and sold 13,042 shares valued at $760,526. 34.60% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/05/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-tesaro-tsro-share-price.html.
Tesaro Company Profile
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Receive News & Ratings for Tesaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro and related companies with MarketBeat.com's FREE daily email newsletter.